Fundraising FoxPulseSight Therapeutics
2 known investors
Find your way into PulseSight Therapeutics
Sign up to see every warm intro you have to PulseSight Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the PulseSight Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness. Its lead programs target late-stage dry AMD/geographic atrophy and wet AMD, with prior Phase 1/2 studies conducted in Europe and the USA.
Investors · 2
How we know: the company's own site · funding news · Not right? Tell us
How we know: Pureos Bioventures's portfolio page · the company's own site · a partner's Signal profile · funding news · pharmafile.com · Not right? Tell us
Funding
SEC filings, press & company announcementsSource: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does PulseSight Therapeutics do?
- PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness. Its lead programs target late-stage dry AMD/geographic atrophy and wet AMD, with prior Phase 1/2 studies conducted in Europe and the USA.
- Who are PulseSight Therapeutics's investors?
- PulseSight Therapeutics's investors include +ND Capital, Pureos Bioventures.